Alessandro Mustazzolu
Overview
Explore the profile of Alessandro Mustazzolu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
229
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sanchini A, Lanni A, Giannoni F, Mustazzolu A
Tuberculosis (Edinb)
. 2024 Jun;
148:102522.
PMID: 38850839
Despite available global efforts and funding, Tuberculosis (TB) continues to affect a considerable number of patients worldwide. Policy makers and stakeholders set clear goals to reduce TB incidence and mortality,...
2.
Mustazzolu A, Piersimoni C, Iacobino A, Giannoni F, Chirullo B, Fattorini L
Ann Ist Super Sanita
. 2019 Apr;
55(1):51-54.
PMID: 30968836
Pyrazinamide (PZA) is a first-line key drug used in combination with other agents for the treatment of tuberculosis (TB). Phenotypic and molecular assays for testing susceptibility of Mycobacterium tuberculosis (Mtb)...
3.
Mustazzolu A, Borroni E, Cirillo D, Giannoni F, Iacobino A, Fattorini L
Eur Respir J
. 2018 May;
52(1).
PMID: 29724919
No abstract available.
4.
Mustazzolu A, Iacobino A, Giannoni F, Piersimoni C, Fattorini L
J Clin Microbiol
. 2017 Sep;
55(12):3552-3553.
PMID: 28904184
No abstract available.
5.
Iacobino A, Piccaro G, Giannoni F, Mustazzolu A, Fattorini L
Int J Mycobacteriol
. 2017 Aug;
6(3):213-221.
PMID: 28776518
Current tuberculosis (TB) treatment requires 6 months of combination therapy with isoniazid (INH), rifampin (RIF), pyrazinamide (PZA), and ethambutol for active TB and 9 months of INH or 3 months...
6.
Del Giudice A, Mustazzolu A, Iacobino A, Perna R, Smeraglia R, Marino R, et al.
Ann Ist Super Sanita
. 2016 Dec;
52(4):603-607.
PMID: 27999235
Background: Drug-resistant tuberculosis (TB) is a serious threat in industrialized countries, but information from Southern Italy is lacking. Here, we present the results of a retrospective study of TB cases...
7.
Iacobino A, Piccaro G, Giannoni F, Mustazzolu A, Fattorini L
Antimicrob Agents Chemother
. 2016 Dec;
61(3).
PMID: 27993848
The activities of rifampin, rifapentine, bedaquiline, PA-824, clofazimine, nitazoxanide, isoniazid, amikacin, moxifloxacin, niclosamide, thioridazine, and pyrazinamide were tested against nonreplicating (dormant) H37Rv under conditions of hypoxia at pHs 5.8 and...
8.
Iona E, Pardini M, Mustazzolu A, Piccaro G, Nisini R, Fattorini L, et al.
J Microbiol
. 2016 Aug;
54(8):565-72.
PMID: 27480637
The physiology of dormant Mycobacterium tuberculosis was studied in detail by examining the gene expression of 51 genes using quantitative Reverse-Transcription Polymerase Chain Reaction. A forty-day period of dormancy in...
9.
Fattorini L, Mustazzolu A, Borroni E, Piccaro G, Giannoni F, Cirillo D
Eur Respir J
. 2016 Feb;
47(4):1273-6.
PMID: 26846829
No abstract available.
10.
Piccaro G, Pietraforte D, Giannoni F, Mustazzolu A, Fattorini L
Antimicrob Agents Chemother
. 2014 Oct;
58(12):7527-33.
PMID: 25288092
The antituberculosis (anti-TB) drug rifampin (RIF) binds to the beta subunit of the RNA polymerase (RpoB) of Mycobacterium tuberculosis, but the bactericidal responses triggered after target interaction are not known....